John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
Boot Barn
BOOT
$4.9B
| $3.71M | 0.01% |
39,165
-88,194
| -69% | -$8.37M |
|
|
TA
1052
DELISTED
TravelCenters of America LLC
TA
| $3.7M | 0.01% |
86,054
+34,191
| +66% | +$1.48M |
|
1053
PJT Partners
PJT
$4.51B
| $3.69M | 0.01% |
58,522
+33,065
| +130% | +$2.15M |
|
1054
Vicor
VICR
$8.76B
| $3.69M | 0.01% |
52,344
+49,241
| +1,587% | +$4.42M |
|
1055
Altimmune
ALT
$605M
| $3.68M | 0.01% |
604,420
+27,998
| +5% | +$206K |
|
1056
Dominion Energy
D
$58.6B
| $3.68M | 0.01% |
+43,326
| New | +$3.48M |
|
1057
Matsons
MATX
$6.66B
| $3.68M | 0.01% |
+30,512
| New | +$3.07M |
|
|
NUBIU
1058
DELISTED
Nubia Brand International Corp. Unit
NUBIU
| $3.67M | 0.01% |
+366,664
| New | +$3.67M |
|
1059
First Merchants
FRME
$2.63B
| $3.67M | 0.01% |
88,109
-42,532
| -33% | -$1.85M |
|
1060
Angi Inc
ANGI
$200M
| $3.65M | 0.01% |
64,356
-12,753
| -17% | -$930K |
|
1061
Rocket Companies
RKT
$39.9B
| $3.62M | 0.01% |
325,791
+173,591
| +114% | +$2.15M |
|
|
EBIX
1062
DELISTED
Ebix Inc
EBIX
| $3.62M | 0.01% |
+109,257
| New | +$3.41M |
|
1063
Autoliv
ALV
$9.02B
| $3.62M | 0.01% |
47,330
-378,739
| -89% | -$34.9M |
|
1064
Wintrust Financial
WTFC
$10.3B
| $3.62M | 0.01% |
+38,902
| New | +$3.79M |
|
|
DEA
1065
Easterly Government Properties
DEA
$1.18B
| $3.61M | 0.01% |
68,255
+715
| +1% | +$38K |
|
1066
Roper Technologies
ROP
$41.1B
| $3.6M | 0.01% |
7,635
-23,964
| -76% | -$10.8M |
|
|
HIBB
1067
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $3.6M | 0.01% |
81,116
+72,925
| +890% | +$3.95M |
|
1068
Revolution Medicines
RVMD
$45.3B
| $3.59M | 0.01% |
140,881
+13,436
| +11% | +$292K |
|
1069
Bank OZK
OZK
$5.38B
| $3.59M | 0.01% |
+84,127
| New | +$3.92M |
|
|
BNT
1070
Brookfield Wealth Solutions
BNT
$12.5B
| $3.59M | 0.01% |
94,200
-9,000
| -9% | -$339K |
|
1071
Canadian Imperial Bank of Commerce
CM
$105B
| $3.59M | 0.01% |
+58,958
| New | +$3.72M |
|
1072
Leggett & Platt
LEG
$1.28B
| $3.58M | 0.01% |
102,893
+18,494
| +22% | +$709K |
|
1073
Health Catalyst
HCAT
$120M
| $3.56M | 0.01% |
+136,113
| New | +$3.86M |
|
1074
Fortinet
FTNT
$112B
| $3.55M | 0.01% |
52,000
-2,184,375
| -98% | -$136M |
|
|
CRON
1075
Cronos Group
CRON
$1.26B
| $3.54M | 0.01% |
911,204
+795,384
| +687% | +$2.9M |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.